2024 December 5th release (#35)

vanallenlab · Dec 6, 2024 · 5a051ba · 5a051ba
1 parent bb3dff5
commit 5a051ba
Show file tree

Hide file tree

Showing 2 changed files with 117 additions and 0 deletions.
diff --git a/docs/content-changelog.md b/docs/content-changelog.md
@@ -1,6 +1,11 @@
 # Content Changelog
 The following changes have been made to the content catalogued within the Molecular Oncology Almanac knowledge base.
 
+## December 2024 release
+Added entries:
+- (FDA) [_KMT2A_ translocations and sensitivity to revumenib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation) for adult and pediatric patients 1 year and older with acute leukemia, entered as acute myeloid leukemia and acute lymphoid leukemia.
+- (FDA) [_NRG1_ fusions and sensitivity to zenocutuzumab-zbco](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic) for adult patients with non-small cell lung cancer and pancreatic adenocarcinoma.
+
 ## November 2024 release
 Added entries:
 - (FDA) [_BCR_::_ABL1_ and sensitivity to asciminib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia) for patients with chronic myeloid leukemia in chronic phase.

diff --git a/molecular-oncology-almanac.json b/molecular-oncology-almanac.json
@@ -33301,5 +33301,117 @@
         "publication_date": "2024-10-10",
         "last_updated": "2024-11-07",
         "_deprecated": false
+    },
+    {
+        "feature_type": "Rearrangement",
+        "gene1": "KMT2A",
+        "gene2": "",
+        "rearrangement_type": "Translocation",
+        "locus": "",
+        "disease": "",
+        "context": "",
+        "oncotree_term": "Acute Myeloid Leukemia",
+        "oncotree_code": "AML",
+        "therapy_name": "Revumenib",
+        "therapy_strategy": "Menin inhibition",
+        "therapy_type": "Targeted therapy",
+        "therapy_sensitivity": 1,
+        "therapy_resistance": "",
+        "favorable_prognosis": "",
+        "predictive_implication": "FDA-Approved",
+        "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
+        "source_type": "FDA",
+        "citation": "Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed December 5, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf",
+        "doi": "",
+        "pmid": "",
+        "nct": "",
+        "publication_date": "2024-11-15",
+        "last_updated": "2024-12-05",
+        "_deprecated": false
+    },
+    {
+        "feature_type": "Rearrangement",
+        "gene1": "KMT2A",
+        "gene2": "",
+        "rearrangement_type": "Translocation",
+        "locus": "",
+        "disease": "",
+        "context": "",
+        "oncotree_term": "Acute Lymphoid Leukemia",
+        "oncotree_code": "ALL",
+        "therapy_name": "Revumenib",
+        "therapy_strategy": "Menin inhibition",
+        "therapy_type": "Targeted therapy",
+        "therapy_sensitivity": 1,
+        "therapy_resistance": "",
+        "favorable_prognosis": "",
+        "predictive_implication": "FDA-Approved",
+        "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
+        "source_type": "FDA",
+        "citation": "Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed December 5, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf",
+        "doi": "",
+        "pmid": "",
+        "nct": "",
+        "publication_date": "2024-11-15",
+        "last_updated": "2024-12-05",
+        "_deprecated": false
+    },
+    {
+        "feature_type": "Rearrangement",
+        "gene1": "NRG1",
+        "gene2": "",
+        "rearrangement_type": "Fusion",
+        "locus": "",
+        "disease": "",
+        "context": "",
+        "oncotree_term": "Non-Small Cell Lung Cancer",
+        "oncotree_code": "NSCLC",
+        "therapy_name": "Zenocutuzumab-zbco",
+        "therapy_strategy": "NRG1 inhibition",
+        "therapy_type": "Targeted therapy",
+        "therapy_sensitivity": 1,
+        "therapy_resistance": "",
+        "favorable_prognosis": "",
+        "predictive_implication": "FDA-Approved",
+        "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.",
+        "source_type": "FDA",
+        "citation": "Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed December 5, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
+        "doi": "",
+        "pmid": "",
+        "nct": "",
+        "publication_date": "2024-12-04",
+        "last_updated": "2024-12-05",
+        "_deprecated": false
+    },
+    {
+        "feature_type": "Rearrangement",
+        "gene1": "NRG1",
+        "gene2": "",
+        "rearrangement_type": "Fusion",
+        "locus": "",
+        "disease": "",
+        "context": "",
+        "oncotree_term": "Pancreatic Adenocarcinoma",
+        "oncotree_code": "PAAD",
+        "therapy_name": "Zenocutuzumab-zbco",
+        "therapy_strategy": "NRG1 inhibition",
+        "therapy_type": "Targeted therapy",
+        "therapy_sensitivity": 1,
+        "therapy_resistance": "",
+        "favorable_prognosis": "",
+        "predictive_implication": "FDA-Approved",
+        "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.",
+        "source_type": "FDA",
+        "citation": "Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed December 5, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
+        "doi": "",
+        "pmid": "",
+        "nct": "",
+        "publication_date": "2024-12-04",
+        "last_updated": "2024-12-05",
+        "_deprecated": false
     }
 ]